Neurocognitive Assessment Platform 4 Alzheimer for Early Detection of Amnestic Mild Cognitive Impairment and Alzheimer's Disease

What this Trial Is About

The increasing aging population in Europe is leading to more cases of neurodegenerative diseases such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050. In Italy alone, there are about 1.2 million dementia cases, half of which are due to AD. Current drug treatments have limited effectiveness, so this study focuses on early, non-drug approaches to slow disease progression and improve quality of life for patients and their caregivers. This study aims to develop the Neurocognitive Assessment Platform 4 Alzheimer (NAP4A), a digital tool designed to detect amnestic mild cognitive impairment (MCIa) early. It uses non-invasive devices like EEG, blood flow sensors, and eye-tracking to gather brain and behavioral data. The study involves 100 participants aged 55 to 80, split into two groups: those diagnosed with MCIa and healthy controls matched by sex, age, and education. Assessments will be done regularly over 12 months to find markers that predict the progression to Alzheimer's. Participants will undergo regular evaluations involving neurophysiological and behavioral measurements using the digital platform. Researchers will track cognitive function and other data to identify early changes that may indicate progression from MCIa to AD. The main outcome is the development of the NAP4A platform over 12 months, alongside identifying key predictive markers. Participants' health and cognitive status will be monitored throughout the study, helping to support early diagnosis and targeted interventions.

Neurocognitive Assessment Platform 4 Alzheimer